A vaccine may cause pancreatic cancer to respond to immunotherapy
Pancreatic ductal adenocarcinomas do not typically respond to immunotherapy, which limits treatment options for this cancer.
Janssen-Cilag International NV Submits EU Marketing Application For...
Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADEA to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma .
Stem cell transplantation for severe sclerosis associated with improved long-term survival
Among patients with a severe, life-threatening type of sclerosis, treatment with hematopoietic stem cell transplantation , compared to intravenous infusion of the chemotherapeutic drug cyclophosphamide, was associated with an increased treatment-related risk of death in the first year, but better long-term survival, according to a study in the June ... (more)
Vaccine May Cause Pancreatic Cancer to Respond to Immunotherapy
Pancreatic ductal adenocarcinomas do not typically respond to immunotherapy, which limits treatment options for this type of cancer.
New vaccine study hopes to improve pancreatic cancer treatment
Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.